RxDoctor Payments Data

Anthony Swanholm, OD

Optometrist · Covington, KYNPI 1609228089

Payments from drug & device makers

$2,654in general payments, 2019–2025

Across 89 payments — averaging $29.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$709
  • Sun Pharmaceutical Industries Inc.$294
  • Bausch & Lomb Americas Inc.$221
  • Rxsight Inc$147
  • Novartis$144
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$139
  • plus $1K from 16 others

What the payments were for

  • Food & beverage$2,654100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,654 in reported general payments places this provider in the 80th percentile of 712 optometrist providers in Kentucky.

See all optometrist providers in Kentucky

Medicare billing

Part B allowed, 2024
$55,525
Medicare patients
311
Services billed
568

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine39$53,825
XiidraLifitegrast26$46,341
Restasis MultidoseCyclosporine21$12,795
LumiganBimatoprost11$6,104
RocklatanNetarsudil Mesylat/Latanoprost14$4,647
Prednisolone Acetate67$1,795
Latanoprost126$1,200
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat27$348
ErythromycinErythromycin Base13$135
Brimonidine Tartrate12$105

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Restasis Multidose, Lumigan$112$72,72471 claims
Bausch & Lomb Americas Inc.Xiidra$221$46,34126 claims
Aerie Pharmaceuticals, Inc.Rocklatan$14$4,64714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 712 optometrist providers in Kentucky.

Other optometrist in Covington

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →